CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124
|
作者：
Maisey, NR [1 ]
Norman, AR [1 ]
Hill, A [1 ]
Massey, A [1 ]
Oates, J [1 ]
Cunningham, D [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期
关键词：
pancreatic cancer; CA19-9; prognosis; chemotherapy;
D O I：
10.1038/sj.bjc.6602760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).
引用
收藏
页码：740 / 743
页数：4
相关论文
共 50 条
  • [31] Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer
    Moriyama, Jin
    Oshima, Yoko
    Nanami, Tatsuki
    Suzuki, Takashi
    Yajima, Satoshi
    Shiratori, Fumiaki
    Funahashi, Kimihiko
    Shimada, Hideaki
    SURGERY TODAY, 2021, 51 (10) : 1638 - 1648
  • [32] Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer
    Wu, Lei
    Huang, Peijun
    Wang, Fang
    Li, Daqian
    Xie, Erfu
    Zhang, Yan
    Pan, Shiyang
    ANNALS OF TRANSLATIONAL MEDICINE, 2015, 3 (21)
  • [33] The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer
    Tanaka, N
    Okada, S
    Ueno, H
    Okusaka, T
    Ikeda, M
    PANCREAS, 2000, 20 (04) : 378 - 381
  • [34] Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer
    Jin Moriyama
    Yoko Oshima
    Tatsuki Nanami
    Takashi Suzuki
    Satoshi Yajima
    Fumiaki Shiratori
    Kimihiko Funahashi
    Hideaki Shimada
    Surgery Today, 2021, 51 : 1638 - 1648
  • [35] Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
    Song, Jian-Yuan
    Chen, Ming-Qiu
    Guo, Jing-Hua
    Lian, Shi-Feng
    Xu, Ben-Hua
    MEDICINE, 2018, 97 (04)
  • [36] Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer
    Xu, Xiangming
    Xiao, Yufei
    Hong, Bo
    Hao, Bing
    Qian, Yun
    CANCER BIOMARKERS, 2019, 25 (03) : 251 - 257
  • [37] Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery
    Ando, Yohei
    Dbouk, Mohamad
    Blackford, Amanda L.
    Yoshida, Takeichi
    Saba, Helena
    Abou Diwan, Elizabeth
    Yoshida, Kanako
    Sokoll, Lori
    Eshleman, James R.
    Burkhart, Richard
    He, Jin
    Goggins, Michael
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (05) : 2902 - 2912
  • [38] Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer
    Jo, Jae-Cheol
    Ryu, Min-Hee
    Koo, Dong-Hoe
    Ryoo, Baek-Yeol
    Kim, Hwa Jung
    Kim, Tae Won
    Choi, Kee Don
    Lee, Gin Hyug
    Jung, Hwoon-Yong
    Yook, Jeong Hwan
    Oh, Sung Tae
    Kim, Byung Sik
    Kim, Jin-Ho
    Kang, Yoon-Koo
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 324 - 330
  • [39] Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer
    Feng, Fan
    Tian, Yangzi
    Xu, Guanghui
    Liu, Zhen
    Liu, Shushang
    Zheng, Gaozan
    Guo, Man
    Lian, Xiao
    Fan, Daiming
    Zhang, Hongwei
    BMC CANCER, 2017, 17
  • [40] CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
    Hartwig, Werner
    Strobel, Oliver
    Hinz, Ulf
    Fritz, Stefan
    Hackert, Thilo
    Roth, Constanze
    Buechler, Markus W.
    Werner, Jens
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (07) : 2188 - 2196
12345